Table 1.

Phase II trials with BRAF inhibitors

Drug	n	ORR (%)	PFS (mo)	OS (mo)
Vemurafenib BRAF V600E[8]	62	37.1	6.51	15.38
Vemurafenib V600E[9]	101	0	5.2	10
Vemurafenib non-V600E[9]	17	44.9	NR	NR
Dabrafenib in 2nd line or beyond[10]	78	33.3	5.5	12.7
Dabrafenib + trametinib in 2nd line or beyond[11]	57	63.2	10.2	18.2
Dabrafenib + trametinib en 1st line[12]	36	64	10.9	24.6

ORR: Overall response rate; PFS: Progression free survival; OS: Overall survival; NR: Not reported.